Benitec Biopharma — First Quarter 2027 Fiscal-Year Earnings Summary

Benitec Biopharma reported positive interim clinical results for its BB-301 therapy in a Phase 1b/2a study for Oculopharyngeal Muscular Dystrophy, showing a 100% responder rate across all patients in Cohort 1 and Cohort 2 with no serious adverse events. The company announced a net loss of $12.9 million for the first quarter ended September 30, 2026, while maintaining approximately $176.5 million in cash and cash equivalents. Benitec plans to finalize the design for its pivotal BB-301 trial in the first quarter of 2027, with the study on track to begin in mid-2027. Additionally, the company intends to transition its fiscal year-end from June 30 to December 31, presenting operational guidance on a calendar-year basis and financial guidance on a fiscal-year basis.